Here are the DEF 14A proxy statements from Arcadia Biosciences, Inc. (RKDA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RKDA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RKDA filings page.
Arcadia Biosciences, Inc. is calling a virtual 2026 annual stockholder meeting on September 10, 2026 at 1:00 p.m. Central Time. Holders of common stock as of the July 29, 2026 record date, when 2,409,211 shares were outstanding, may vote.
Stockholders will elect one Class II director (incumbent Gregory D. Waller) and vote on: (1) approving, under Nasdaq Listing Rule 5635(d), the potential issuance of up to 3,993,296 shares of common stock upon exercise of Series A‑1 preferred investment options sold in a June 12, 2026 private placement, which could provide up to approximately $3.5 million in gross proceeds if fully exercised for cash; (2) approving the 2026 Omnibus Equity Incentive Plan; and (3) authorizing a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑10, at the Board’s discretion before June 30, 2027, to help regain compliance with Nasdaq’s $1.00 minimum bid requirement following an August 4, 2026 deficiency notice.
Additional items include a nonbinding advisory vote on executive compensation, ratification of Ramirez Jimenez International CPAs as independent auditors for 2026, and an adjournment proposal. The Board, which has five members (four deemed independent), recommends voting FOR all proposals. Significant investors include Sabby Volatility Warrant Master Fund and Armistice Capital Master Fund, each limited to 9.9% beneficial ownership by agreement.
Arcadia Biosciences, Inc. (RKDA) is asking stockholders to vote at its 2025 annual meeting, to be held virtually on December 19, 2025 at 1:00 p.m. Central Time. Stockholders will be asked to elect three Class I directors (Albert D. Bolles, Kevin Comcowich and CEO Thomas J. Schaefer), approve on an advisory basis the compensation of named executive officers, and ratify Deloitte & Touche LLP as independent registered public accountants for the year ending December 31, 2025.
The meeting is online only, accessible at www.virtualshareholdermeeting.com/RKDA2025 using a 16-digit control number. The Board recommends voting FOR all three proposals. Stockholders of record at the close of business on November 4, 2025, when 1,373,120 shares of common stock were outstanding, are entitled to vote one vote per share. The proxy describes Arcadia’s classified seven‑member board structure, committee memberships, director and executive pay, and ownership levels of directors, officers and key investors.